Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$2.95 USD

2.95
429,641

+0.10 (3.51%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $2.94 -0.01 (-0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y

Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.

Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of 550% and 6.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates

Intercept (ICPT) delivered earnings and revenue surprises of -35.09% and 7.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top

Puma Biotechnology's (PBYI) Q4 2022 loss is wider than estimates, Revenues beat the same.

CERT vs. PBYI: Which Stock Should Value Investors Buy Now?

CERT vs. PBYI: Which Stock Is the Better Value Option?

Puma Biotechnology, Inc. (PBYI) Hits Fresh High: Is There Still Room to Run?

Puma Biotech (PBYI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is Puma Biotechnology (PBYI) Stock a Solid Choice Right Now?

Puma Biotechnology (PBYI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Gilead (GILD) Outperforms YTD: Will It Retain the Momentum?

Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.

Is Biogen (BIIB) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion

Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?

PBYI vs. GMAB: Which Stock Is the Better Value Option?

Viatris (VTRS) Wins in Court Against AstraZeneca's Symbicort

Viatris (VTRS) and its partner win a court decision that invalidates branded drug Symbicort's patent and opens the door for them to launch their generic version of the drug.

Clovis (CLVS) Plummets on News of Possible Bankruptcy Filing

Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.

Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion

Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemotherapy, irrespective of PD-L1 expression levels.

Axsome (AXSM) Q3 Loss Narrower Than Expected, Revenues Miss

Axsome (AXSM) reports a narrower-than-expected loss in the third quarter. Revenues comprise sales of the sleep drug, Sunosi, acquired from Jazz.

Amicus (FOLD) Q3 Earnings Beat, Galafold Sales Miss Estimates

Amicus Therapeutics (FOLD) posts a narrower-than-expected loss in the third quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.

bluebird (BLUE) Q3 Earnings Top, Revenues Miss Estimates

While the commercial launch of Zynteglo is underway, bluebird's (BLUE) Q3 losses narrow but revenues miss estimates.

Viatris (VTRS) Q3 Earnings Beat, Revenues Miss Estimates

Viatris (VTRS) beats on Q3 earnings but misses sales estimates as fluctuations in foreign exchange rates continue to impact results. The company reaffirms guidance.

Bausch (BHC) Q3 Earnings & Sales Miss, Guidance Lowered

Bausch (BHC) Q3 earnings and sales decline year over year due to the unfavorable impact of foreign exchange rates. The company also lowers its annual guidance.

Intra-Cellular (ITCI) Beat on Q3 Earnings and Sales Estimates

Intra-Cellular Therapeutics (ITCI) posts a narrower-than-expected Q3 loss and sales also beat the mark. ITCI continues to advance its pipeline with developmental programs.

Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss

Agios Pharmaceuticals (AGIO) posts narrower-than-expected Q3 loss while sales miss estimates. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.

Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y

Intellia Therapeutics (NTLA) posts a wider-than-expected Q3 loss and sales also miss the mark. NTLA continues to advance its pipeline with developmental programs.

Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up

Puma Biotech (PBYI) beats earnings and revenue estimates for third-quarter 2022. It increases product revenue guidance for full-year 2022 to reflect improving demand trends for Nerlynx in the United States.